HomeInsightsStock Comparison

Cohance Lifesciences Ltd vs Vivimed Labs Ltd Stock Comparison

Cohance Lifesciences Ltd vs Vivimed Labs Ltd Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

  • The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 429.5 as of 18 May 16:01 . The P/E Ratio of Cohance Lifesciences Ltd changed from 34.8 on March 2021 to 110.3 on March 2025 . This represents a CAGR of 25.95% over 5 yearsThe P/E Ratio of Vivimed Labs Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Cohance Lifesciences Ltd changed from ₹ 12611 crore on March 2021 to ₹ 29524 crore on March 2025 . This represents a CAGR of 18.55% over 5 yearsThe Market Cap of Vivimed Labs Ltd changed from ₹ 131.42 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 5 years The revenue of Cohance Lifesciences Ltd for the Mar '26 is ₹ 617.28 crore as compare to the Dec '25 revenue of ₹ 550.71 crore. This represent the growth of 12.09% The revenue of Vivimed Labs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 15.99 crore. This represent the decline of -100% The ebitda of Cohance Lifesciences Ltd for the Mar '26 is ₹ 80.33 crore as compare to the Dec '25 ebitda of ₹ 96.65 crore. This represent the decline of -16.89% The ebitda of Vivimed Labs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ -10.92 crore. This represent the decline of -100% The net profit of Cohance Lifesciences Ltd changed from ₹ 75.37 crore to ₹ 8.31 crore over 8 quarters. This represents a CAGR of -66.80% The net profit of Vivimed Labs Ltd changed from ₹ -15.25 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Cohance Lifesciences Ltd changed from 16.5 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Vivimed Labs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Cohance Lifesciences Ltd

  • Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018.
  • The name of the Company has been changed to Cohance Lifesciences Limited w.e.f.
  • May 7, 2025.
  • Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
  • The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

About Vivimed Labs Ltd

  • Vivimed Labs Limited was originally incorporated on September 22, 1988 as a private limited company in the name of Emgi Pharmaceuticals & Chemicals Pvt Ltd. On April 21, 1994, the company got converted into a public limited company and the name was changed to Emgi Pharmaceuticals & Chemicals Ltd and thereafter, the Company name was finally changed to Vivimed Labs Limited on April 22, 1997. The Company is engaged in manufacturing of Specialty Chemicals (mainly used in Personal Care and Cosmetic Industry), Pharmaceuticals, API's and Formulations.
  • The company has strong presence in the areas of Health & Personal Care, Contract Research and Manufacturing.
  • The company has four subsidiary companies, namely Creative Health Care Pvt Ltd, Vivimed Holdings Ltd (Hong Kong), Vivimed Labs Europe Ltd (UK) and Vivimed Labs USA Inc.

FAQs for the comparison of Cohance Lifesciences Ltd and Vivimed Labs Ltd

Which company has a larger market capitalization, Cohance Lifesciences Ltd or Vivimed Labs Ltd?

Market cap of Cohance Lifesciences Ltd is 16,190 Cr while Market cap of Vivimed Labs Ltd is 54 Cr

What are the key factors driving the stock performance of Cohance Lifesciences Ltd and Vivimed Labs Ltd?

The stock performance of Cohance Lifesciences Ltd and Vivimed Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cohance Lifesciences Ltd and Vivimed Labs Ltd?

As of May 18, 2026, the Cohance Lifesciences Ltd stock price is INR ₹423.2. On the other hand, Vivimed Labs Ltd stock price is INR ₹6.6.

How do dividend payouts of Cohance Lifesciences Ltd and Vivimed Labs Ltd compare?

To compare the dividend payouts of Cohance Lifesciences Ltd and Vivimed Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions